Moderna Withdraws Application for Combination COVID-19–Influenza Vaccine

The pharmaceutical company said it plans to resubmit the application at a later date.

A sign marks the headquarters of vaccine maker Moderna in Cambridge, Mass., on April 28, 2022. Brian Snyder/Reuters

Moderna on May 21 said it withdrew its application for a license for its combination vaccine against COVID-19 and influenza.

The move came “in consultation with” the Food and Drug Administration, which decides on licensing applications, the Massachusetts-based pharmaceutical company said in a brief statement.